Moncef Slaoui, Ph.D., specializes in the research and development of vaccines and Pharmaceuticals and was recognized as one of Fortune’s “50 Greatest World Leaders” in 2016 for his work in under-researched diseases common in the developing world.
Slaoui’s career spanned 29 years at GlaxoSmithKline (GSK) and was active on its board of directors between May of 2006 and March 2017. He was chairman of global research and development (R&D) between 2006 and 2014, where he led an overhaul of the company’s pharmaceutical R&D and was also responsible for commercial pursuits such as new product launches and life cycle management. Slaoui was also chairman of GSK’s vaccine division from 2009 until his retirement from the company in June 2017. Early in his career while working in vaccines R&D at GSK, he was instrumental in the development of the vaccines Rotarix®, to prevent infantile rotavirus gastroenteritis; Synflorix®, to prevent pneumococcal disease; Cervarix®, to prevent cervical cancer, Mosquirix™ to prevent plasmodium malaria disease and Shingrix™ to prevent shingles.
After his retirement from GSK, Slaoui joined Medicxi Life Sciences venture capital firm as a partner; he also took on a number of independent board positions including chairman of the board of Galvani, a Bioelectronics focused company jointly owned by GSK and Verily life sciences, and independent board director of Moderna, Sutrovax, and Artizan Biotechnology companies.
Slaoui earned a Ph.D. in molecular biology and immunology from the Université Libre de Bruxelles in Belgium, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston, and was a professor of immunology at the University of Mons, Belgium.